✦ LIBER ✦
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
✍ Scribed by Benson, C; White, J; Bono, J De; O'Donnell, A; Raynaud, F; Cruickshank, C; McGrath, H; Walton, M; Workman, P; Kaye, S
- Book ID
- 109999022
- Publisher
- Nature Publishing Group
- Year
- 2006
- Tongue
- English
- Weight
- 173 KB
- Volume
- 96
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.